Cochrane · systematic review · CD009458
Oral and intrauterine progestogens for atypical endometrial hyperplasia
Luo, L, Luo, B, Zheng, Y, et al. · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
Gynaecology and FertilityAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
3
current version
GRADE rated
3
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 2 · 66.7%Low 1 · 33.3%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Levonorgestrel‐releasing intrauterine system (LNG‐IUS) compared to medroxyprogesterone (MPA) 10 mg for atypical endometrial hyperplasia
Population: women with atypical endometrial hyperplasia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Regression rate at 6 months Levonorgestrel‐releasing intrauterine system (LNG‐IUS) vs medroxyprogesterone (MPA) 10 mg | OR 2.76 [0.26, 29.73] | 1 study · 19 participants | Very low Downgraded: imprecision, indirectness |
Nausea over 6‐month Levonorgestrel‐releasing intrauterine system (LNG‐IUS) vs medroxyprogesterone (MPA) 10 mg | OR 0.58 [0.28, 1.18] | 1 study · 153 participants | Very low Downgraded: imprecision, indirectness |
Vaginal bleeding over 6‐month Levonorgestrel‐releasing intrauterine system (LNG‐IUS) vs medroxyprogesterone (MPA) 10 mg | OR 2.89 [1.11, 7.52] | 1 study · 153 participants | Low Downgraded: indirectness |